Health Insurance (Section 3C General Medical Services – Botox Injection) Determination 2020

The Determination rests on a small set of definitional and application concepts it supplies and imports from the Act. The instrument defines “Act” to mean the Health Insurance Act 1973 and defines “relevant provisions” to mean all provisions of the Act and regulations made under the Act and the National Health Act 1953 and regulations under that Act that relate to medical services, professional services or items (s 4(1)). This is a broad incorporative definition: the instrument does not itself restate the content of those provisions, but it expressly treats the specified relevant service as if it were governed by them.

A “relevant service” is defined by the instrument to mean a health service as defined in subsection 3C(8) of the Act that is specified in a Schedule to the instrument (s 4(1)). The instrument therefore relies on the Act’s embedded definition of “health service” and the statutory concept of “clinically relevant service” referred to in its notes. The phrase “clinically relevant service” appears in the instrument’s note that subsection 3(1) of the Act defines that term, alongside “general medical services table”, “item” and “professional service”. The instrument therefore presumes that readers will apply the Act’s substantive definitions when determining whether a service is “clinically relevant”.

Section 5 is the operational linchpin. It prescribes that where a relevant service is provided in accordance with the instrument and as a clinically relevant service, it is to be treated, for the relevant provisions, as if it were both a professional service and a medical service and as if there were an item in the general medical services table related to the service with a fee specified in relation to each State (the fee being the fee specified in the Schedule). This converts the service into the equivalent of an MBS item for the purposes of the relevant provisions without directly amending the general medical services table itself.

Section 6 applies two discrete clauses of the general medical services table, namely clause 5.8.1 and clause 5.8.2, as if item 18361 were specified there. The instrument does not reproduce the text of those clauses; it simply aligns the new item with their application. Users of the instrument must therefore read those clauses in the general medical services table alongside this Determination to understand the detailed billing and entitlement rules that will apply.

Section 7 introduces an indexation concept. It sets an indexation time of 1 July 2025 and prescribes that fees listed in the Schedule are to be multiplied by 1.024 at that time, with a specified rounding rule to the nearest 5 cents and a note about the MBS Online website as the place to view indexed fees. The Schedule itself contains the particular item 18361, its textual description including specific brand names of botulinum toxin products, clinical indication limitations (moderate to severe upper limb spasticity due to cerebral palsy), age criteria (patient at least 2 years), and quantitative limits on sets of injections per day and per upper limb.

Taken together, the core concepts are: (1) the conversion of a specified procedure into an MBS-equivalent item for application of the Act and related provisions; (2) the embedding of that item within certain billing operational clauses of the general medical services table; and (3) a prospective indexation of the Schedule fee at a fixed date using a fixed multiplier and rounding rule.

The Determination creates effects for multiple actors by changing how a specified botulinum toxin injection service is treated under the Act and related legislation. The instrument’s own language identifies the classes of legal provisions that will apply to the service by defining “relevant provisions” to mean all relevant provisions under the Health Insurance Act 1973 and the National Health Act 1953 and their regulations (s 4(1)). That definitional choice makes the list of affected actors a function of who participates in, administers, bills under, or is regulated by those statutory regimes.

Primary affected parties

• Clinicians and service providers who deliver the specified service. The Schedule specifies a service described as “Clostridium Botulinum Type A … injection … for the treatment of moderate to severe upper limb spasticity due to cerebral palsy” with particular eligibility criteria and limits (Schedule, Item 18361). Providers who deliver that service and wish to claim under the relevant provisions must ensure the service is provided “in accordance with this instrument and as a clinically relevant service” (s 5). The provider’s entitlement to treat the service as both a professional and a medical service and to claim the fee is therefore contingent on meeting the instrument’s descriptive and clinical eligibility requirements.

• Patients receiving the specified service. The Schedule confines the item to patients at least 2 years of age and to the clinical indication of moderate to severe upper limb spasticity due to cerebral palsy. It further limits the scope of service on a per-day and per-limb basis (a maximum of 4 sets of injections per patient on any one day, maximum of 2 sets per upper limb) (Schedule, Item 18361). These criteria determine whether a claim under the relevant provisions for item 18361 is available for a particular patient encounter.

• Administrators of the Act and the National Health Act regimes. Because the instrument treats the service “for the relevant provisions” as if an MBS item exists with a fee specified in each State (s 5), bodies responsible for administering benefits and checking compliance under those Acts will be responsible for processing claims, applying operational rules imported by s 6, and enforcing the applicable compliance, audit and recovery mechanisms contained in the relevant provisions.

Other affected parties and practical implications

• Billing and practice administrators. The instrument sets a single fee in the Schedule ($145.65) and states that it is to be treated as a fee in relation to each State (s 5(b)(ii) and Schedule). Billing systems and practice management software will need to map the specific service description and item number 18361 to that fee and to the operational clauses cited in s 6.

• Specialists and anaesthesia providers. The Schedule description includes the notation “(Anaes.)”, which signals the classification of the item within the general medical services table framework. While the Determination does not elaborate on the operational consequences of that notation, clinicians must be aware that the item’s text includes that parenthetical and that clause 5.8.1 and 5.8.2 are applied to it (s 6). This may affect which practitioner bills or how the item interacts with other anaesthetic or procedural claims under the relevant provisions.

• Suppliers and manufacturers are limited in the sense that the Schedule lists specific product names (Dysport, Botox, Xeomin). The item’s text therefore ties the MBS-equivalent description to named preparations; whether other preparations are captured for billing under this item depends on the literal wording in the Schedule.

• State-level payers and systems. Section 5(b)(ii) frames the fee as a fee “in relation to each State, being the fee specified in the Schedule”. The instrument therefore imposes a fee with state application rather than different state-by-state fees. State health systems that coordinate Commonwealth benefit payments or interact with MBS billing will need to recognise this fee as the national figure to be applied under the relevant provisions.

Who does not automatically gain a new entitlement

• Providers offering the same toxin injection for other indications, different patient age groups, or different anatomical targets are not covered for item 18361 by the language of the Schedule. The instrument’s scope is limited to the specifically described clinical use and conditions. Claims for other services will need to rely on other items or provisions, if available, under the Act and the National Health Act.

In short, the Determination affects clinicians who provide the specifically described botulinum toxin injection and seek to bill under the relevant provisions, the patients who meet the narrow eligibility criteria in the Schedule, and the administrative and billing systems that process and enforce claims under the Health Insurance Act and the National Health Act, operating in accordance with the general medical services table clauses that the instrument expressly applies to item 18361.

The Determination creates a set of substantive and procedural duties and rights for parties interacting with the specified service by converting the service into an MBS-equivalent item for the purposes of the Act and related legislation. These duties and rights are derived from the instrument’s operative provisions and from the fact that it imports the operative framework of the general medical services table and the “relevant provisions”.

Rights created

• Right to treat the service as both a professional service and a medical service under the relevant provisions. Section 5(a) provides that, where the service is provided in accordance with the instrument and as a clinically relevant service, it is to be treated as both a professional and a medical service for the relevant provisions. This creates an entitlement to rely on the procedural rules and benefit frameworks that apply to those categories under the Act and the National Health Act and their regulations.

• Right to claim the specified fee. Section 5(b) instructs that the service is to be treated as if there were an item in the general medical services table that specified a fee in relation to each State, and that the fee is the one specified in the Schedule. The Schedule sets the fee for item 18361 at $145.65. That fee therefore becomes the fee that applies to claims under the relevant provisions for this item, subject to later indexation under s 7.

• Right to have clauses 5.8.1 and 5.8.2 of the general medical services table apply to the item. Section 6 specifies that those clauses shall have effect as if item 18361 were specified there. That right is operational: it ensures the item is processed under the same rules those clauses impose.

Duties imposed

• Duty to provide the service in accordance with the instrument and as a clinically relevant service. The treatment of the service as an MBS-equivalent item is conditional upon the service being provided in accordance with the instrument and as a clinically relevant service (s 5). The instrument does not restate the Act’s definition of “clinically relevant service”; it therefore imposes a duty on providers to ensure the Act’s criteria are met when claiming under item 18361.

• Duty to meet the Schedule’s eligibility and scope conditions. The Schedule limits the item to a specified clinical indication , treatment of moderate to severe upper limb spasticity due to cerebral palsy , and to patients aged at least 2 years. It also sets quantitative limits on injections: a maximum of four sets of injections for the patient on any one day and a maximum of two sets of injections for each upper limb, including all injections per set (Schedule, Item 18361). Providers must ensure claims respect these clinical and quantitative constraints.

• Duty to observe the billing and operational rules that apply to items in the general medical services table, especially clause 5.8.1 and subclause 5.8.2(1) as applied by s 6. The instrument does not recode those operational rules, but it brings them to bear on item 18361. That creates duties in relation to how the item is billed, whether combined with other items, and any other requirements those clauses impose.

• Duty to apply indexation and rounding rules when the indexation time arrives. Section 7 directs that at the indexation time of 1 July 2025 each Schedule fee be replaced by the amount worked out by multiplying by 1.024, and that the resulting amount be rounded to the nearest 5 cents with the discrete rule that it be rounded down if the amount is an exact multiple of 2.5 cents (s 7(1) and (3)). Administrative actors must apply that arithmetic when determining the fee to be used after indexation.

Ancillary duties and implied responsibilities

• The instrument requires providers and administrators to interpret the Schedule’s textual limits, including the product names specified (Dysport, Botox, Xeomin). The presence of these names in the Schedule’s description suggests that the item is tied to those formulations. Parties must therefore ensure that the product used fits the Schedule description when lodging a claim.

• The administrative apparatus must map item 18361 into billing systems and reporting, ensuring the fee is applied “in relation to each State” as the instrument prescribes (s 5(b)(ii)).

• Because the Determination treats the service “for the relevant provisions” as if an item exists in the general medical services table, providers and administrators inherit any recordkeeping, compliance, audit or eligibility duties that the relevant provisions and the general medical services table impose.

The instrument does not itself spell out penalties for non‑compliance; it instead situates the item within the existing statutory frameworks that attach rights and duties and that contain enforcement and recovery mechanisms. Practitioners and administrators should therefore read the instrument together with the Act, the National Health Act and the regulations and the specified clauses of the general medical services table to identify the full suite of rights and duties that will govern claims, recordkeeping and enforcement.

The Determination does not itself create offences or penalties. It operates by treating a specified relevant service as if it were an item in the general medical services table for the purpose of the “relevant provisions” as defined in s 4(1). That definition expressly includes “all provisions, of the Act and regulations made under the Act, and the National Health Act 1953 and regulations made under the National Health Act 1953, relating to medical services, professional services or items.” Because the instrument brings the specified service within the existing statutory frameworks, enforcement, compliance monitoring, penalty regimes and any financial recovery mechanisms will be those that the relevant provisions of the Health Insurance Act 1973, the National Health Act 1953 and their regulations provide.

Practical consequences of that legal structure

• Enforcement is delegated to the frameworks already established by the Act and the National Health Act. The instrument does not purport to vary or create new sanctions; instead it subjects activity under item 18361 to the same enforcement machinery that applies to other medical and professional services and items under the existing laws. Readers must therefore consult those statutes and regulations to identify specific audit processes, administrative penalty regimes, recovery procedures and criminal or civil offence provisions that might attach to false or improper claims.

• Application of clause-based rules. Section 6 declares that clause 5.8.1 of the general medical services table shall have effect as if item 18361 were specified in that clause, and that clause 5.8.2 shall have effect as if item 18361 were specified in subclause 5.8.2(1). Any compliance obligations, limitations on claiming, bundling rules, or other regulatory mechanics contained in those clauses will therefore attach to item 18361 and will be enforceable under the relevant provisions’ overall enforcement mechanisms.

• Financial risk. Because the instrument inserts the item into the “relevant provisions” regime, improper claims may attract recovery of benefit payments, and potentially other administrative consequences, in accordance with those provisions. The Determination itself does not state recovery procedures. Entities making or processing claims must therefore apply the recovery, audit and penalty provisions in the Act and the National Health Act where applicable.

• Indexation and fee changes. Section 7’s indexation rule will change the numerical fee at the indexation time. Administrative errors in applying the indexation formula or rounding rule could produce incorrect payments and therefore trigger recoveries or adjustments under the relevant provisions.

Scope for administrative discretion and audit

• The instrument’s treatment of the service as a clinically relevant service requires a factual assessment to be made in each claim: whether the service is clinically relevant as defined by the Act. That factual assessment will be subject to review under the audit and compliance powers found in the relevant provisions, not under any novel or separate enforcement mechanism created by this instrument.

• The instrument’s cross-reference to clause 5.8.1 and clause 5.8.2 of the general medical services table means that administrators will apply interpretation and discretion in accordance with those clauses when determining entitlement and compliance. The Determination itself leaves that interpretive work to the administrators charged with enforcing the relevant provisions.

In short, the Determination does not set out novel penalties but places the new item squarely within the established statutory compliance, audit and penalty architecture of the Health Insurance Act 1973, the National Health Act 1953 and their regulations. Parties seeking to understand the precise enforcement or recovery consequences of non-compliance with item 18361 must consult the relevant provisions incorporated by the instrument.

The Determination is expressly designed to operate by reference to, and within, existing Commonwealth legislative frameworks. The instrument’s own definitions and operative clauses specify the inter‑legal relations that apply.

Primary statutory interactions

• Health Insurance Act 1973. The instrument is made under subsection 3C(1) of the Health Insurance Act 1973 (see s 3 of the instrument). It also directs that a relevant service specified in its Schedule be treated “for the relevant provisions” as if there were an item in the general medical services table. Given the instrument’s reliance on the Act for both authority and definitional content (for example, the note that several terms are defined in subsection 3(1) of the Act), users must read the Determination alongside the relevant parts of the Health Insurance Act to understand how the conversion of the specified service into an MBS-equivalent item operates in practice.

• National Health Act 1953. The instrument’s definition of “relevant provisions” includes not only provisions of the Health Insurance Act and its regulations but also provisions of the National Health Act 1953 and regulations made under that Act that relate to medical services, professional services or items (s 4(1)). This means that the Determination’s reach extends beyond the Health Insurance Act to the suite of legal mechanisms in the National Health Act that apply to items and professional services.

• The general medical services table. The instrument imports operational clauses from the general medical services table by reference. Section 6 requires that clause 5.8.1 shall have effect as if item 18361 of this Determination was specified in the clause, and that clause 5.8.2 shall have effect as if item 18361 was specified in subclause 5.8.2(1). The Determination therefore does not operate in isolation; it relies on and modifies the application of specific general medical services table rules to include item 18361. To understand billing interactions, practitioners must read those clauses alongside this Determination.

Consequential interactions and administrative implementation

• Benefit processing and audit. Because the Determination treats the service “for the relevant provisions” as if it were an MBS item, processing of claims, eligibility determinations, audits and recoveries will be conducted under the procedural and enforcement rules contained in the Health Insurance Act, the National Health Act and their regulations. The Determination therefore intersects with the enforcement and administrative apparatus of those laws.

• Indexation and MBS Online. Section 7’s indexation mechanism points users to the Department of Health and Aged Care’s MBS Online website as the location where indexed fees could be viewed. This signals an administrative integration with the MBS publication and fee update processes used for other items. The Determination does not itself create a separate publication regime but relies on existing administrative channels to communicate indexation changes.

• Product specification and regulatory coverage. The Schedule’s text lists specific botulinum toxin preparations by name (Dysport; Botulinum Toxin Type A Purified Neurotoxin Complex (Botox); IncobotulinumtoxinA (Xeomin)). The inclusion of those names in the item description anchors the Determination’s scope to specific products. How that product specification interacts with other regulatory regimes governing medicines, product substitution, or professional practice (for example, the Therapeutic Goods Act if relevant) is not stated in the instrument. The Determination confines itself to the coverage and billing effects under the Act and the National Health Act.

Limitations and reading obligations

• The instrument repeatedly points back to definitions and provisions in the Health Insurance Act. For example, “relevant service” is defined by reference to subsection 3C(8) of the Act, and the note refers to definitions in subsection 3(1). Practitioners therefore need to reconcile the instrument with those source provisions, because the Determination relies on their operative meanings.

• The Determination does not amend the general medical services table directly; instead it treats the specified service as if an item existed in that table and applies particular clauses to it. Consequently, legal interpretation will require a joint reading of this instrument, the general medical services table clauses cited, and the relevant provisions of the Health Insurance Act and the National Health Act.

In sum, the Determination interacts with other laws primarily by incorporation. It depends on the Health Insurance Act 1973 for authority and definitional content, by reference folds the National Health Act 1953 into the set of “relevant provisions”, and aligns the new item with specified clauses of the general medical services table, while relying on existing administrative channels for publication and indexation.

The instrument identifies itself as the Health Insurance (Section 3C General Medical Services - Botox Injection) Determination 2020 (s 1). The text supplied contains no express amending provisions, statutory notes of repeal or modification, nor any schedules indicating later variation. It contains, however, a prospective indexation adjustment scheduled to occur at 1 July 2025 (s 7). That indexation provision is internal to this instrument: it will modify the numerical fees specified in the Schedule at the indexation time by applying the 1.024 multiplier and by rounding to the nearest 5 cents in accordance with s 7(1) and (3).

What the instrument records about change

• Original enactment. The instrument’s name and s 3 identify its parent statutory authority and year: it is made under subsection 3C(1) of the Health Insurance Act 1973 and is the 2020 Determination. The document as provided does not reproduce the original date of registration or commencement clauses beyond the authority and the indexation time; those administrative dates would typically appear on the instrument as made and registered, but they are not included in the supplied text.

• Prospective indexed adjustment. Section 7 constitutes an automatic, built-in alteration of the Schedule fees at a named indexation time. The instrument therefore contains a built-in single-step amendment mechanism limited to numeric indexation at a specified date, rather than a general power to be revisited periodically. The precise mechanics are: at 1 July 2025 replace each Schedule fee by the amount equal to 1.024 times the amount immediately before that time, then round to the nearest 5 cents, with a downward rounding if the amount is an exact multiple of 2.5 cents (s 7(1)-(3)).

No recorded subsequent amendments in the supplied text

• The supplied instrument text does not show any later amendments or variants. It contains a single Schedule (Schedule 1 - relevant services) with a solitary item, item 18361. No variation or updating history is recorded in the instrument text provided.

How to interpret the absence of an amendment log in this text

• If a practitioner needs to know whether the Determination has been amended after the version provided, the instrument itself gives no such history. The instrument’s note that indexed fees could be viewed on the Department’s MBS Online website (s 7 Note) implies that the public and administrators will use that resource to view current fees and any later changes. For the legal status of the Determination, practitioners should consult the official register of legislative instruments and MBS publications to determine whether subsequent legislative instruments or administrative actions have varied this Determination.

In short, the instrument as supplied contains no explicit amendment history apart from the built-in indexation event. There are no amending schedules or annotations in the supplied text indicating that it has been modified since its 2020 form.

The text of the Determination supplied contains no references to litigation, judicial decisions, or cases. It does not cite any judicial interpretation, nor does it note any prior disputes or determinations that have been the subject of legal proceedings. The instrument therefore has no litigation history recorded within its own text.

What this implies for users

• No cases named in the instrument. There are no cases or authorities cited in the Determination; consequently, there is no on-instrument jurisprudential guidance on the meaning, scope, or application of item 18361 or on the interaction between this Determination and other provisions.

• Application and potential disputes will be governed by the relevant provisions. Any enforcement, dispute or judicial review concerning claims under item 18361 will be adjudicated under the administrative and legal frameworks in the Health Insurance Act 1973, the National Health Act 1953 and their regulations, and by reference to the general medical services table clauses that are applied to the item. Because the Determination incorporates those regimes, litigation about the Determination’s application will necessarily involve interpretation of those Acts and of the general medical services table.

• Absence of recorded cases in the instrument. The Determination itself does not record or summarise any case law or tribunal decisions. Parties interested in disputes, precedential interpretation or challenge should look to decisions arising from the general medical services table and the broader relevant provisions rather than to this instrument’s text.

In brief, the instrument contains no litigation history. Questions about its interpretation or enforcement would be resolved within the existing judicial and administrative frameworks established under the Health Insurance Act, the National Health Act and the MBS operational rules.

The Determination’s brevity means a number of practical pitfalls and attention points arise that are not spelled out in the instrument but that follow directly from its structure and wording. Below are concrete operational and legal issues users must note, grounded in the instrument’s text.

Narrow clinical scope and product specification

• The Schedule confines item 18361 to the treatment of “moderate to severe upper limb spasticity due to cerebral palsy” and to patients “at least 2 years of age” (Schedule, Item 18361). The item cannot be read to cover injections for other indications, other anatomical targets, or younger patients. Claims for other clinical uses are not captured by this item.

• The Schedule names specific formulations: Dysport, Botox and Xeomin. The descriptive wording therefore ties the item to those preparations. Whether alternative botulinum toxin preparations qualify requires scrutiny of the literal wording; the instrument’s text as supplied does not authorise claims for unlisted products.

Counting sets and injections per day

• The Schedule limits the service to “a maximum of 4 sets of injections for the patient on any one day (with a maximum of 2 sets of injections for each upper limb), including all injections per set” (Schedule, Item 18361). Practitioners must track how “sets” are defined in clinical practice and in billing systems. The instrument does not define “set” nor the unit of counting for injections within a set. The ambiguity creates a risk of incorrect claims if providers count injections differently from what administrators expect under the general medical services table clauses imported by s 6.

Interaction with clause-based rules

• Section 6 brings clause 5.8.1 and clause 5.8.2 into play for item 18361. Those clauses may contain bundling, exclusion or aggregation rules relevant to how item 18361 is claimed alongside other items or procedures. The Determination does not reproduce the clauses; therefore failing to consult the general medical services table may result in improper billing. The practical “gotcha” is to assume the item is freely claimable without reading those clauses.

Indexation mechanics

• The indexation uses a fixed multiplier 1.024 applied at a single indexation time, 1 July 2025 (s 7). The instrument replaces each fee by the result of that multiplication and then rounds to the nearest 5 cents with a precise rounding rule (s 7(3)). Errors in applying the multiplier or rounding rule will produce incorrect fee amounts. Administrative staff must implement the arithmetic exactly as stated: multiply by 1.024, then round to nearest 5 cents with the specific downward rounding if amount is exact multiple of 2.5 cents.

Anaesthesia notation

• The Schedule concludes with the parenthetical “(Anaes.)”. The instrument does not explain the operational consequence of that notation. In the MBS context that notation typically signals a particular classification or fee relationship to anaesthetic services. The “gotcha” is to ignore that notation; instead practitioners must treat it as material for how item 18361 is to be billed or combined with other claims, again by consulting the clauses the instrument applies.

“Clinically relevant service” condition

• Section 5 conditions the treatment of the service on it being provided “as a clinically relevant service”. The instrument does not restate the Act’s criteria for that term. A claimable service therefore requires a factual determination that the service meets the Act’s definition of clinically relevant service. Failing to make or document that determination could expose a claim to recovery under the relevant provisions.

State fee application

• Section 5(b)(ii) specifies that the item fee is to be treated as a fee in relation to each State, with the Schedule specifying the fee. Despite differences that sometimes exist across jurisdictions, the instrument expressly fixes the Schedule fee as the fee to be applied in relation to each State. Practitioners should not attempt to apply different state‑level fees under this item unless and until the relevant provisions are lawfully varied.

Documentation and audit exposure

• Because the Determination situates the item within the existing statutory framework, claims will be subject to the usual audit and recovery mechanisms in the relevant provisions. The lack of express recordkeeping directions in the Determination means providers should not assume a relaxed documentation standard. The practical risk is that insufficient clinical records or failure to document age, diagnosis, muscle/nerve target, and counts of sets will make a claim vulnerable to recovery.

Administrative publication and currency

• The instrument notes that indexed fees could be viewed on the Department’s MBS Online website (s 7 Note). The “gotcha” here is to rely solely on the instrument text for fee amounts without checking MBS Online for the current indexed fee after 1 July 2025, or for any subsequent administrative adjustments.

In short, the main operational pitfalls are: assuming broader clinical coverage than the Schedule provides; miscounting or mis‑classifying sets of injections; failing to consult and apply clause 5.8.1 and 5.8.2 of the general medical services table; misapplying the indexation and rounding formula; overlooking the (Anaes.) notation; and insufficient documentation to satisfy the “clinically relevant service” condition and potential audits under the relevant provisions.

Compliance with the Determination requires reading it in tandem with the Health Insurance Act 1973, the National Health Act 1953 and the general medical services table provisions that the Determination expressly applies. The instrument places the specified service within that broader legal and administrative framework and does not restate all operative rules, so practical compliance depends on synthesising requirements across instruments.

Immediate steps for clinicians and practice administrators

1. Confirm clinical eligibility before claiming. For each patient, document that the injection is for “moderate to severe upper limb spasticity due to cerebral palsy” and that the patient is at least 2 years of age, as required by Schedule, Item 18361. Ensure the clinical record states the diagnosis and the clinical rationale for the injection and that it demonstrates the service meets the Act’s definition of “clinically relevant service”.

2. Track and record sets and injections. The Schedule caps injections to a maximum of four sets for the patient on any one day and to a maximum of two sets per upper limb, “including all injections per set”. Maintain contemporaneous records that record (a) the date, (b) the number of sets administered that day, (c) the number of sets per limb, (d) the muscles treated and the motor nerve supplying them, and (e) doses per injection. Adopt an internal definition for “set” that is consistent with clinical practice and with any interpretations provided in clause 5.8.1 or clause 5.8.2 of the general medical services table, then use that definition consistently.

3. Confirm product used matches Schedule description. The Schedule lists specific product names. Document the exact product used and batch information if necessary. If using a preparation not explicitly named in the Schedule, do not assume eligibility for item 18361 without checking whether the item description and the general medical services table permit it.

4. Apply the correct item number and fee. When billing, use item 18361 and apply the Schedule fee as the fee to be treated “in relation to each State” (s 5(b)(ii)). Monitor the MBS Online site for any administrative updates and for the new fee after the indexation time on 1 July 2025. At indexation, replace the pre‑indexation fee by multiplying by 1.024 and rounding to the nearest 5 cents as required by s 7(1)-(3).

5. Observe clause-based billing rules. Read clause 5.8.1 and clause 5.8.2 in the general medical services table and apply them to item 18361, as required by s 6. Those clauses may specify bundling rules, exclusion of certain concurrent claims or requirements about anaesthesia-related billing that will affect how item 18361 is processed.

6. Retain evidence that the service was provided “in accordance with this instrument”. The entitlement to treat the service as an MBS-equivalent item depends on compliance with the instrument’s terms (s 5). Keep documentation that demonstrates the service met the Schedule criteria and any requirements in the general medical services table clauses applied by s 6.

Administrative and systems steps

7. Update billing systems and staff training. Map item 18361 into practice management and billing software with the correct fee and link it to documentation checklists capturing age, diagnosis, muscle/nerve information, number of sets and product used. Train billing staff to recognise that the item is governed by clause 5.8.1 and clause 5.8.2 and to apply those rules.

8. Implement audit-ready recordkeeping. Given that item 18361 is treated under the “relevant provisions”, which include the Act’s compliance and recovery mechanisms, maintain records sufficient to demonstrate clinical eligibility and conformity with the daily/limb set limits. Include date-stamped clinical notes, consent forms, product dispensing records and a clear audit trail for each claim.

9. Prepare for indexation and rounding. From an administrative perspective, design a process to apply the indexation formula at 1 July 2025: multiply the pre-indexation fee by 1.024 and round to the nearest 5 cents per s 7(1)-(3). Implement system updates so that claims lodged on or after the indexation time use the updated amount.

10. Liaise with administrative authorities if in doubt. Because the Determination imports rules from the general medical services table and other statutes, contact the relevant administering agency or consult MBS Online for guidance on interpretation and on how clause 5.8.1 and clause 5.8.2 operate in practice for item 18361.

Audit and compliance controls

11. Embed pre-claim checks. Require a clinician attestation or checklist before submitting a claim for item 18361 that confirms the patient met the age and diagnosis criteria, that the number of sets complies with the daily/limb limits, and that the product used is described in the Schedule.

12. Maintain product traceability. Keep records of product name and batch number to support the claim where the Schedule explicitly names the toxin preparations. This reduces the risk of a claim being rejected or subject to recovery.

13. Reconcile payments against MBS Online. After payments are processed, reconcile the amounts received against the Schedule fee and any indexed fee published on MBS Online to detect mis‑payments promptly and to correct billing procedures.

Legal checks

14. Read the Health Insurance Act, the National Health Act and the general medical services table provisions together with the Determination. The Determination conditions the entitlement upon the service being a “clinically relevant service” and applies specific clauses from the general medical services table. To ensure legal compliance, examine the relevant statutory definitions and clauses for any additional constraints, exceptions or recordkeeping obligations.

15. Seek specialist advice if the clinical situation is borderline. Where the indication, product, age criterion or counting of sets is ambiguous, obtain legal or administrative advice before lodging a claim, to mitigate the risk of recovery under the “relevant provisions”.

Following these steps will align clinical practice and billing with the Determination’s textual requirements and with the cross-referenced operational rules the instrument applies. The key compliance principle is to treat the item as subject to the full suite of rules contained in the Health Insurance Act, the National Health Act and the general medical services table clauses that the Determination expressly brings into effect for item 18361.